INUS
Straddle Chart

Markets / Mutual funds / Index Funds (equity)

Mutual fundsSIF

Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Regular Plan - Growth

NAVs of 6 Nov 2026

Edelweiss Mutual Fund · Index & ETFs fund · Regular plan · Growth

Index Funds (equity)Regular · GrowthRisk: Very High
NAV · 5 Nov 2026
₹24.7076 ▼ 0.53%
Edelweiss Mutual Fund
Fund size₹195 crJuly - September 2026
1-month range₹22.98 – 24.84
1 year+21.72%rank 5 of 376
Expense ratio1.10%regular plan, a year
5 years+14.70%a year

What the fund does

The Scheme will invest in stocks comprising of the MSCI India Domestic IMI and World Healthcare Select Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors. However, there is no assurance that the investment objective of the Scheme will be realized and the Scheme does not assure or guarantee any returns.

BenchmarkMSCI India Domestic & World Healthcare 45 Index
Launched26 Oct 2020
Fund houseEdelweiss Mutual Fund
Fund managersBhavesh Jainsince 1 Oct 2021Manasi Jalgaonkarsince 1 Apr 2026Amit Vora (for investments in foreign securities)since 2 Dec 2021

NAV history

232425 2026-08-102026-08-212026-09-032026-09-182026-10-012026-10-152026-10-29

Returns

1 week
+2.41%avg 4.3%
1 month
+5.54%avg 3.4%
3 months
+3.74%avg -1.8%
6 months
+15.42%avg 0.6%
This year
+18.73%avg -0.3%
1 year
+21.72%avg 0.2% · #5/376
3 years (a year)
+21.26%avg 10.4% · #4/187
5 years (a year)
+14.70%avg 9.1% · #3/58

Bars: this plan; the thin mark is the Index Funds (equity) average (regular plans, growth option). Over a year: yearly averages (CAGR). Past returns do not guarantee future returns. Information only, not investment advice.

Monthly returns (%)

YearJanFebMarAprMayJunJulAugSepOctNovDec
2024+1.8
2025-3.0-3.0+2.5-0.4-0.7+3.1+4.0-2.8-1.2+4.4+4.9-1.8
2026-2.3+5.5-4.6+2.5+3.7+5.7+3.7+2.4-3.6+3.9+1.1

Each month's change in NAV (the current month to the latest NAV).

What if you had invested?

Worked out from this plan's actual NAVs. SIP: invested on the first NAV of each month. Taxes and exit loads are not included. Past returns do not guarantee future returns. Information only, not investment advice.

Portfolio as on 30 Sept 2026

Stocks held4548 lines in all
Top 10 stocks55.0%of the fund
Equity99.9%stocks and equity derivatives
Debt & cash0.1%everything else

Where the money is

Equity 99.9%Cash & others 0.1%Short -0.0%

Sectors (stocks held)

Pharmaceuticals & Biotechnology
55.2%
Pharmaceuticals
16.1%
Healthcare Services
14.3%
Biotechnology
7.0%
Health Care Equipment & Supplies
5.0%
Life Sciences Tools & Services
2.4%

Stocks held 45

HoldingSector / type% of fund
Sun Pharmaceutical Industries Ltd.
INE044A01036		Pharmaceuticals & Biotechnology10.45%
Divi's Laboratories Ltd.
INE361B01024		Pharmaceuticals & Biotechnology7.09%
ELI LILLY & CO
US5324571083		Pharmaceuticals6.46%
Apollo Hospitals Enterprise Ltd.
INE437A01024		Healthcare Services5.25%
JOHNSON & JOHNSON
US4781601046		Pharmaceuticals4.45%
Laurus Labs Ltd.
INE947Q01028		Pharmaceuticals & Biotechnology4.44%
Torrent Pharmaceuticals Ltd.
INE685A01028		Pharmaceuticals & Biotechnology4.38%
Cipla Ltd.
INE059A01026		Pharmaceuticals & Biotechnology4.34%
Max Healthcare Institute Ltd.
INE027H01010		Healthcare Services4.19%
Dr. Reddy's Laboratories Ltd.
INE089A01031		Pharmaceuticals & Biotechnology3.95%
ABBVIE INC
US00287Y1091		Biotechnology3.22%
Lupin Ltd.
INE326A01037		Pharmaceuticals & Biotechnology2.97%
Aurobindo Pharma Ltd.
INE406A01037		Pharmaceuticals & Biotechnology2.77%
MERCK & CO.INC
US58933Y1055		Pharmaceuticals2.50%
Fortis Healthcare Ltd.
INE061F01013		Healthcare Services2.41%
Glenmark Pharmaceuticals Ltd.
INE935A01035		Pharmaceuticals & Biotechnology2.11%
NOVARTIS AG
US66987V1098		Pharmaceuticals1.82%
THERMO FISHER SCIENTIFIC INC
US8835561023		Life Sciences Tools & Services1.75%
IPCA Laboratories Ltd.
INE571A01038		Pharmaceuticals & Biotechnology1.72%
Mankind Pharma Ltd.
INE634S01028		Pharmaceuticals & Biotechnology1.65%
AMGEN INC
US0311621009		Biotechnology1.59%
Biocon Ltd.
INE376G01013		Pharmaceuticals & Biotechnology1.47%
Alkem Laboratories Ltd.
INE540L01014		Pharmaceuticals & Biotechnology1.38%
Gland Pharma Ltd.
INE068V01023		Pharmaceuticals & Biotechnology1.37%
Zydus Lifesciences Ltd.
INE010B01027		Pharmaceuticals & Biotechnology1.37%
GILEAD SCIENCES INC
US3755581036		Biotechnology1.29%
ABBOTT LABORATORIES
US0028241000		Health Care Equipment & Supplies1.20%
Aster DM Quality Care Ltd.
INE914M01019		Healthcare Services1.04%
Ajanta Pharma Ltd.
INE031B01049		Pharmaceuticals & Biotechnology1.01%
INTUITIVE SURGICAL INC
US46120E6023		Health Care Equipment & Supplies1.00%
DANAHER CORP
US2358511028		Health Care Equipment & Supplies0.98%
VERTEX PHARMACEUTICALS INC
US92532F1003		Biotechnology0.93%
Novo Nordisk A/S
US6701002056		Pharmaceuticals & Biotechnology0.85%
MEDTRONIC PLC
IE00BTN1Y115		Health Care Equipment & Supplies0.77%
Global Health Ltd.
INE474Q01031		Healthcare Services0.70%
Narayana Hrudayalaya ltd.
INE410P01011		Healthcare Services0.70%
GlaxoSmithKline Pharmaceuticals Ltd.
INE159A01016		Pharmaceuticals & Biotechnology0.67%
STRYKER CORP
US8636671013		Health Care Equipment & Supplies0.66%
Wockhardt Ltd.
INE049B01025		Pharmaceuticals & Biotechnology0.62%
Anthem Biosciences Ltd.
INE0CZ201020		Pharmaceuticals & Biotechnology0.55%
Regeneron Pharmaceuticals Inc
US75886F1075		Pharmaceuticals0.55%
BECTON DICKINSON AND CO
US0758871091		Health Care Equipment & Supplies0.34%
AGILENT TECHNOLOGIES INC
US00846U1016		Life Sciences Tools & Services0.34%
IQVIA HOLDINGS INC
US46266C1053		Life Sciences Tools & Services0.31%
WATERS CORP
US9418481035		Pharmaceuticals0.30%

Short positions 1

HoldingSector / type% of fund
Net Receivables/(Payables)–-0.01%

Debt, money market and cash 2

HoldingSector / type% of fund
Clearing Corporation of India Ltd.–0.10%
Accrued Interest–0.00%

From the fund house's monthly portfolio (edelweissmf.com), as on 30 Sept 2026. Percentages are of the fund's net assets. Published about ten days after each month ends.

Risk

Volatility11.7%yearly, from daily NAVs
Worst fall-12.78%31 Dec 2021 → 30 Jun 2022
RiskometerVery HighVery High

Volatility: how much the NAV moves, as a yearly figure (higher = bumpier). Worst fall: the biggest drop from a high, in the NAV history we hold (from 31 Dec 2020).

Fund details

Fund size (average AUM, July - September 2026)₹195 cr across all plans · this plan ₹115 cr
Fund houseEdelweiss Mutual Fund
CategoryIndex & ETFs · Index Funds (equity)
PlanRegular
OptionGrowth
Expense ratio (TER)Direct 0.56% · Regular 1.10% (5 Nov 2026)
Scheme code (AMFI)148557
ISININF754K01LR3
NAV date5 Nov 2026

Scheme details from the fund's scheme summary document filed with AMFI; expense ratios from AMFI's daily filings.

Other plans of this fund

PlanNAV1 year
Direct · Growth₹25.5649+22.38%
Direct · IDCW₹22.5491+7.94%
Regular · IDCW₹21.6956+6.88%

Top Index Funds (equity) funds (regular plans)

Fund1 year3 years (a year)
ICICI Prudential NASDAQ 100 Index Fund+10.81%+25.41%
Motilal Oswal S&P 500 Index Fund+15.40%+23.79%
ICICI Prudential Nifty Pharma Index Fund+22.94%+22.18%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund+21.72%+21.26%
ICICI Prudential Nifty Auto Index Fund+4.46%+20.29%
Motilal Oswal BSE Enhanced Value Index Fund-2.47%+19.95%
UTI Nifty 500 Value 50 Index Fund+2.35%+19.85%
Motilal Oswal BSE Enhanced Value Index Fund-3.11%+19.14%

All Index Funds (equity) funds ranked › · Compare with others ›

← All mutual funds

Information only, not investment advice.

What is the NAV of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Regular Plan - Growth today?

₹24.7076 as of 5 Nov 2026, from AMFI's official NAV data.

What are the returns of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Regular Plan - Growth?

1 year: 21.72%, 3 years: 21.26% a year, 5 years: 14.70% a year

How does Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund rank in its category?

5 of 376 Index Funds (equity) funds (regular plans, growth option) by 1-year return.

What is the difference between direct and regular plans?

Both invest in the same portfolio. Direct plans are bought straight from the fund house and pay no distributor commission, so their expenses are lower and their NAV grows slightly faster.